MedPath

Alflutinib

Generic Name
Alflutinib
Drug Type
Small Molecule
Chemical Formula
C28H31F3N8O2
CAS Number
1869057-83-9
Unique Ingredient Identifier
A49A7A5YN4

Overview

Alflutinib is under investigation in clinical trial NCT03452592 (Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients With T790M).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2022/01/26
Phase 2
Not yet recruiting
The First Affiliated Hospital of Henan University of Science and Technology
2018/12/27
Phase 3
Active, not recruiting
Allist Pharmaceuticals, Inc.
2018/03/02
Phase 2
Terminated
Allist Pharmaceuticals, Inc.
2017/04/25
Not Applicable
Terminated
Allist Pharmaceuticals, Inc.
2016/11/25
Phase 1
Terminated
Allist Pharmaceuticals, Inc.

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.